Stock Groups

J&J Gains as FDA Says Its Covid Booster Shot Helps Immunity By Investing.com

by Mike Robinson

[ad_1]

© Reuters.

By Dhirendra Tripathi

Investing.com – Johnson & Johnson stock (NYSE:) rose by 0.5% in Wednesday’s trading as the Food and Drug Administration said the company’s booster shot against Covid-19 helped boost immune response.

The regulators cautioned that data was limited and they relied on the company’s own analysis for some of the findings, rather than conducting their own study.

The regulator’s view comes in response to the company’s request for authorization of its booster dose.

The following are the results so far Pfizer (NASDAQ:) BioNTech (NASDAQ) booster has been the only one approved to be administered to people over 60 or to high-risk individuals.

Along with J&J’s request, the FDA has before it a request from Moderna For its booster dose, please visit (NASDAQ:).

The J&J shot is the only one in the U.S. carrying a single-dose application. All other vaccines are double-dose.

J&J recommends that a booster be given six months after the initial shot, though it could be given as early as two months also after the first.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]